Frequent hypermethylation of the 5′ region of p15 but not p16 in patients with MDS
| Patient . | Age/sex . | MDS subtype . | Bone marrow blasts (%) . | Cytogenetic risk . | IPSS . | 1-mCp15 (%) . | 1-mCp16 (%) . |
|---|---|---|---|---|---|---|---|
| 001 | 72/M | CMMoL | 15 | INT | High | 48 | 4 |
| 002 | 80/M | RAEB-t | 30 | Poor | High | 10 | 5 |
| 003 | 76/F | RAEB-t | 25 | Poor | High | 27 | 6 |
| 004 | 65/F | RA | < 5 | INT | INT-1 | 27 | 3 |
| 005 | 64/M | RAEB | 8 | INT | INT-2 | 35 | 1 |
| 006 | 73/M | CMMoL | 2 | NN | INT-1 | 28 | 8 |
| 007 | 75/F | RAEB-t | 25-30* | Poor | High | 48 | 2 |
| 008 | 64/M | RAEB-t | 30 | INT | High | 29 | 3 |
| 009 | 64/M | RAEB-t | 21 | NN | High | 12 | 1 |
| 010 | 55/F | RA | < 5 | Poor | INT-2 | 27 | 10 |
| 011 | 78/M | RA | < 5 | Good | INT-1 | 4 | 1 |
| 012 | 75/F | RAEB | 15 | INT | INT-2 | 32 | 1 |
| 013 | 72/F | RAEB | 20 | Poor | High | 27 | ND |
| 014 | 61/F | RA | < 5 | NN | INT-1 | 16 | 2 |
| 015 | 52/F | RAEB | 9 | NN | INT-1 | 8 | 4 |
| 016 | 64/M | RAEB-t | 30 | Poor | High | 45 | 8 |
| 017 | 64/M | CMMoL | < 5 | NN | INT-1 | 5 | 1 |
| 018 | 62/F | sAML | 60 | Poor | — | 54 | 4 |
| 019 | 62/F | RAEB | 20 | INT | High | 28 | 1 |
| 020 | 69/F | RAEB-t | 24 | NN | High | 10 | 9 |
| 021 | 61/M | RAEB-t | 28 | Poor | High | 13 | 1 |
| 022 | 78/F | sAML | 41 | ND | — | 42 | ND |
| 023 | 34/F | RA | < 5 | Poor | INT-2 | 7 | ND |
| Patient . | Age/sex . | MDS subtype . | Bone marrow blasts (%) . | Cytogenetic risk . | IPSS . | 1-mCp15 (%) . | 1-mCp16 (%) . |
|---|---|---|---|---|---|---|---|
| 001 | 72/M | CMMoL | 15 | INT | High | 48 | 4 |
| 002 | 80/M | RAEB-t | 30 | Poor | High | 10 | 5 |
| 003 | 76/F | RAEB-t | 25 | Poor | High | 27 | 6 |
| 004 | 65/F | RA | < 5 | INT | INT-1 | 27 | 3 |
| 005 | 64/M | RAEB | 8 | INT | INT-2 | 35 | 1 |
| 006 | 73/M | CMMoL | 2 | NN | INT-1 | 28 | 8 |
| 007 | 75/F | RAEB-t | 25-30* | Poor | High | 48 | 2 |
| 008 | 64/M | RAEB-t | 30 | INT | High | 29 | 3 |
| 009 | 64/M | RAEB-t | 21 | NN | High | 12 | 1 |
| 010 | 55/F | RA | < 5 | Poor | INT-2 | 27 | 10 |
| 011 | 78/M | RA | < 5 | Good | INT-1 | 4 | 1 |
| 012 | 75/F | RAEB | 15 | INT | INT-2 | 32 | 1 |
| 013 | 72/F | RAEB | 20 | Poor | High | 27 | ND |
| 014 | 61/F | RA | < 5 | NN | INT-1 | 16 | 2 |
| 015 | 52/F | RAEB | 9 | NN | INT-1 | 8 | 4 |
| 016 | 64/M | RAEB-t | 30 | Poor | High | 45 | 8 |
| 017 | 64/M | CMMoL | < 5 | NN | INT-1 | 5 | 1 |
| 018 | 62/F | sAML | 60 | Poor | — | 54 | 4 |
| 019 | 62/F | RAEB | 20 | INT | High | 28 | 1 |
| 020 | 69/F | RAEB-t | 24 | NN | High | 10 | 9 |
| 021 | 61/M | RAEB-t | 28 | Poor | High | 13 | 1 |
| 022 | 78/F | sAML | 41 | ND | — | 42 | ND |
| 023 | 34/F | RA | < 5 | Poor | INT-2 | 7 | ND |
Methylation of both 5′ regions was measured by Ms-SNuPE as described in “Patients, materials, and methods.”
MDS subtypes: RA indicates refractory anemia; RAEB, refractory anemia with excess of blasts; RAEB-t, refractory anemia with excess of blasts in transformation. CMMoL indicates chronic myelomonocytic leukemia; sAML, progression to secondary acute myeloid leukemia at time of treatment start; NN, normal karyotype; cytogenetic risk, cytogenetic risk score (good: normal karyotype, −Y, del [5q], del [20q]; poor: complex [at least 3 abnormalities] or chromosome 7 anomalies; intermediate [INT]: other abnormalities); IPSS, International Prognostic Scoring System32;
C (%), methylation status in percentage measured by Ms-SNuPE; ND, not determined.
Bone marrow histology.